Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Ltd. have announced a partnership to develop a clinical-stage pain treatment asset, FZ002-037, targeting SSTR4.
FZ002-037 is a highly selective oral small-molecule SSTR4 agonist developed by Fermion. Preclinical studies indicate that the drug primarily provides peripheral analgesia without central side effects or addiction risks, making it a promising option for patients requiring long-term pain management.
It is the first domestically developed SSTR4 agonist in China and the second globally to reach the clinical stage. The drug has completed Phase I clinical trials in China, with Phase II studies for diabetic peripheral neuropathy set to begin soon. Potential applications extend to various chronic and acute pain conditions.
Dr. Deco Deng, Founder of Fermion, stated, “As the first domestically developed and the world's second high-selectivity SSTR4 agonist to enter the clinical stage, FZ002-037 holds great promise. By leveraging Simcere's strong development and commercialization capabilities, we are confident in accelerating its progress to provide better treatment options for patients suffering from pain.”
Zhou Gaobo, Chief Investment Officer of Simcere, added, “Pain significantly affects patients' quality of life and remains a major unmet clinical need. Addressing these 'clinical pain points' has always been a core mission for Simcere. We look forward to collaborating with innovative partners like Fermion to deliver more effective and safer pain therapies to patients as quickly as possible.”
Under the agreement, Simcere will gain exclusive rights to develop and commercialise FZ002-037 in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). Fermion will receive an upfront payment, milestone payments, and tiered royalties based on future sales.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy